Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?
Heart failure (HF) represents the end-stage condition of several structural and functional cardiovascular diseases, characterized by reduced myocardial pump function and increased pressure load. The dysregulation of neurohormonal systems, especially the hyperactivity of the cardiac adrenergic nervou...
Main Authors: | Leonardo Bencivenga, Maria Emiliana Palaia, Immacolata Sepe, Giuseppina Gambino, Klara Komici, Alessandro Cannavo, Grazia Daniela Femminella, Giuseppe Rengo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/2/457 |
Similar Items
-
Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses
by: Ruxu Zhai, et al.
Published: (2022-03-01) -
GRK2-Dependent HuR Phosphorylation Regulates HIF1α Activation under Hypoxia or Adrenergic Stress
by: Clara Reglero, et al.
Published: (2020-05-01) -
Suitability of GRK Antibodies for Individual Detection and Quantification of GRK Isoforms in Western Blots
by: Mona Reichel, et al.
Published: (2022-01-01) -
Targeting GRK5 for Treating Chronic Degenerative Diseases
by: Federica Marzano, et al.
Published: (2021-02-01) -
Effects of low level of lead exposure on blood pressure and responsiveness of the rat isolated heart to adrenergics
by: Badalzadeh R., et al.
Published: (2008-06-01)